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Expression of ErbB4 in the neurons of 
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Abstract: Neuregulin-1 (NRG1) plays important roles in the development and plasticity of the brain, and has also been 
reported to exhibit potent neuroprotective properties. Although ErbB4, a key NRG1 receptor, is expressed in multiple regions 
in the adult animal brain, little is known about its role in Alzheimer’s disease (AD). AD is characterized by progressive 
impairment of cognition and behavioral disturbance that strongly correlate with degeneration and death of neurons in the 
cerebral cortex and limbic brain areas, such as the hippocampus and the amygdala. Here, we show that the ErbB4 and phospho-
ErbB4 immunoreactivities were higher intensity in the neurons of the CA1-2 transitional fi  eld of AD brains as compared to age-
matched controls. Also, ErbB4 expression was increased in the neurons of the cortico medial nucleus amygdala, human basal 
forebrain and superior frontal gyrus of AD brains. In cerebral cortex and hippocampus of amyloid precursor protein/presenilin 
1 double transgenic mice, ErbB4 immunoreactivity signifi  cantly increased in comparison to age-matched wild type control. 
Th   ese results suggest that up-regulating of ErbB4 immunoreactivity may involve in the progression of pathology of AD.
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in the genes encoding amyloid precursor protein (APP) 
and presenilins (PS1 and PS2). Transgenic mouse models 
expression APP and presenilin variants associated with 
familial AD have provided important insights into structural, 
neurophysiologic, and behavioral eff  ects of Aβ accumulation 
in the brain [2]. 
Neuregulin-1 (NRG1) signaling participates in numerous 
neurodevelopmental processes, and is implicated in nerve 
cell differentiation and synapse formation [3, 4], radial glia 
formation and neuronal migration [5, 6], oligodendrocyte 
development and axon myelination [7, 8], axon navigation 
[9], and neurite outgrowth [10, 11]. NRG1 and its receptor 
ErbB tyrosine kinases are expressed not only in the 
developing nervous system, but also in adult brain. In the 
adult, NRG1 signaling suppresses both the induction and 
the expression of long-term potentiation at CA1 synapses 
and stimulates gamma-aminobutyric acid (GABA) release 
Introduction 
Alzheimer’s disease (AD), the most common form of 
dementia, is a chronic neurodegenerative disease causing 
progressive impairment of memory and other cognitive 
functions. Pathologically, the AD brain is characterized 
by two types of lesion: senile or neuritic plaques and 
neurofi  brillary tangles (NFT). Neuronal and synaptic loss are 
the essential neuropathological feature in AD, thus leading 
to severe impairment of neurotransmission and resulting in 
a decline in cognitive abilities [1]. Research on AD has been 
greatly stimulated by the identifi  cation of causative mutations ErbB4 in the neurons of Alzheimer’s disease
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in response to depolarization. Inhibition of NRG1 signaling 
in hippocampal slices from postnatal mice destabilizes 
synaptic AMPA receptors and leads to the loss of synaptic 
N-methyl D-aspartate (NMDA) and spines [12]. These 
findings suggest additional functions of NRG1 signaling 
in the mature nervous system. NRG1 acts by stimulating a 
family of single-transmembrane receptor tyrosine kinases 
called ErbB [13]. NRG1 function is largely mediated by a 
class of receptor tyrosine kinases including ErbB2, ErbB3, 
and ErbB4 [14, 15]. ErbB4 is likely to be the major mediator 
of NRG1 functions in the brain. Especially ErbB4 is the only 
autonomous NRG1-specifi  c ErbB that can both interact with 
the ligand and become activated by it as a tyrosine kinase. 
ErbB4 tyrosin kinase is expressed in multiple regions not only 
in the developing brain, but also in the adult brain [16, 17]. 
Th   e function of NRG1 in the brain has gained much attention 
since the initial discovery [18] and subsequent confi  rmation 
[19] that nrg1 gene is linked to schizophrenia. Further studies 
showed that erbB4 gene, but not erbB2 or 3, has been shown 
to associate with schizophrenia [20, 21]. A subgroup of 
patients with late-onset AD also develops psychosis during 
progression of the disease (AD with psychosis). Psychotic 
symptoms in AD are typically defined by the presence of 
delusions and hallucinations [22]. A recent study suggests 
that NRG1 plays a role in increasing the genetic risk to 
positive symptoms of psychosis in a proportion of late-onset 
AD families [23]. Th   e aim of our study is to further explore 
the involvement of ErbB4 in AD pathogenesis. We herein 
investigate the detailed histopathological changes in the 
neuron of AD brains and APP/PS1 double transgenic mice. 
Materials and Methods 
Reagents and antibodies
Antibodies were supplied by Santa Cruz Biotechnology Inc. 
(ErbB4, sc-283, sc-8050; p-ErbB4, sc-33040) (Santa Cruz, CA, 
USA) and COVANCE (beta-amyloid, SIG-39320) (Emeryville, 
CA, USA). Vectashield (H-1000), biotinylated anti-rabbit IgG 
(BA-1000) and biotinylated anti-mouse IgG (BA-2001) were 
supplied by Vector Laboratories (Burlingame, CA, USA). 
Hoechst 33342 (bis-benzimide H33342 trihydrochloride, 
14533) and DAB (3,3'-diaminobenzidine tetrahydrochloride, 
D-5905) were supplied by Sigma Aldrich (St. Louis, MO, 
USA). 
Human tissues preparation and histochemical 
staining
Fourteen age-matched control brains with no clinical or 
neuropathologic evidence of AD were obtained within 24 
postmortem hours from the cadavers of the Department 
of Anatomy and Neuroscience, School of Medicine at 
Eulji University. Consent was given for brain donation by 
next-of-kin in all cases, and a postmortem examination 
was conducted by the Anatomy laboratory according to 
standardized protocols. All experimental procedures were 
performed in accordance with ‘The Guidelines of the 
Institutional Review Board (Ethics Committee) at Eulji 
University.’ A total of fourteen hemispheres of brains obtained 
by autopsy were fi  xed in 10% neutral buff  ered formalin. Th  e 
fi  xed hemispheres were cut in coronal plane, and blocks were 
selected from 10 to 15 brain areas for pathologic diagnosis 
and a comprehensive evaluation of the neurodegenerative 
process. Th   ey were prepared according to routine histological 
procedures for paraffi   n section. Th  e  fi  ft  een Alzheimer brains 
were generously gifted from Dr. Roger A. Brumback and 
were diagnosed by him (Department of Pathology, School of 
Medicine, Creighton University, Omaha, NE, USA). All brains 
were processed according to same protocols. The sections 
were cut in coronal plane at 8 μm for immunohistochemical 
study or 20 μm for confocal microscopic immunofl  uorescence 
study, and then mounted on poly-L-lysine coated slides. 
Th   e sections were deparaffi   nized and hydrated according to 
routine graded xylene-alcohol methods. Hematoxylin and 
eosin (H&E) and Luxol fast blue/cresyl violet (LFB-CV) stains 
were done for general histopathology and modified silver 
stain by Campbell et al. [24] for detecting the senile plaque 
and Gallyas stain [25] for NFT were employed. Th  e  modifi  ed 
Campbell’s silver staining method is a combination of the 
Campbell and Gallyas stain. Th   e technique was modifi  ed in 
our laboratory for the detection of brain amyloid and NFT 
in humans. Briefly, deparaffinized slides are placed into 
a pyridine silver solution for the induction of nucleation 
sites, which is followed by incubation in a Gallyas’ physical 
developer solution for 8-10 minutes. The sections are then 
checked under the microscope. The Gallyas developer is 
composed of three solutions. Solution A contains 50 g of 
sodium carbonate dissolved in 1,000 ml of distilled water 
(DW). Solution B contain 2 g of ammonium nitrate, 2 g of 
silver nitrate, and 10 g of tungstosilicic acid dissolved in 1,000 
ml of DW. Solution C is the same as the B solution, except 7 
ml of 40% formol is added. All solutions are mixed prior to Anat Cell Biol 2011;44:116-127 Ran-Sook Woo, et al 118
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the staining process (8 : 10 : 2 vol %; sol. A : sol. B : sol. C). 
The process is then fixed in 3% sodium thiosulfate solution 
in order to remove the unreacted silver and stop the silver 
impregnation and then rinsed in tap water for 30 minutes. 
Th   e detailed data of each brain is summarized in Table 1.
Animals and tissue preparation
Th   e mouse model used in this study was the double trans-
genic APPSwe/PS1 (B6C3-Tg (APPswe, PSEN1dE9)85Dbo/
J) from Jackson Laboratories (Bar Harbor, Maine). APPSwe is 
the Swedish mutation of the amyloid precursor protein, and 
PS1 is the mutant form of human presenilin 1. Th  e  sixteen-
month-old wild type and transgenic mice were anesthetized 
with a mixture (0.01 mg/g body weight, i.p.) of ketamine 
(10 mg/ml) and rumpun (1 mg/ml). Mice were subjected to 
intracardiac perfusion-fixation using 4% paraformaldehyde 
dissolved in phosphate buff  ered saline (PBS), pH 7.4. Brains 
were removed and then prepared according to routine 
histological procedures for paraffi   n sectioning. Th  e  sections, 
cut 6 μm in thickness, were deparaffinized and hydrated 
according to routine graded xylene-alcohol methods. H&E 
stain was done for general histopathology.
Immunohistochemistry
In order to retrieve antigenecity, dewaxed sections were 
boiled within 0.1 mol/L citrate-buff  ered saline (pH 6.0) for 10 
minutes. Aft  er cooling down for 30 minutes, the sections were 
rinsed in PBS. The endogenous peroxidase was quenched 
by 1% hydrogen peroxide in 10% methanol for 30 minutes. 
Aft  er two changes of PBS-T (0.1% Triton X-100 in 0.1 mol/L 
PBS, pH 7.6) washing for 5 minutes respectively, the sections 
were blocked for 1 hour in blocking solution (5% host 
serum+1% bovine serum albumin in PBS-T) and incubated 
in primary antibody (1 : 200, anti-ErbB4 and 1 : 200, APP) 
at 4°C overnight. After PBS-T rinses, the sections were 
incubated in a biotinylated secondary antibody for 1 hour 
at room temperature (RT). Aft  er PBS rinsing and an avidin-
biotin-peroxidase complex (Vectastain Elite ABC kit, Vector 
Laboratories) treatment for 1 hour at RT, the sections were 
developed for 5 minutes in a 0.05% DAB solution. Images 
were captured with a Axiocam digital camera (MRC, Carl 
Zeiss Inc., GÖttingen, Germany) attached on the Olympus 
AX70 microscope (Olympus Co., Tokyo, Japan). 
       
Confocal immunofl  uorescence
Immunofluorescence was performed as previously 
described [26]. In brief, the prestaining process was the same 
as above. Normal horse serum was then applied for 1 hour 
to block nonspecific background staining. Then sections 
were incubated with avidin-biotin blocking solution (Vector 
Laboratories) and incubated overnight at 4°C in blocking 
solution containing rabbit anti-ErbB4 (1 : 50). Following 
this, they were washed and incubated with the appropriate 
secondary biotinylated antibody and after rinsing, the 
sections were incubated with FITC avidin D. The sections 
Table 1. Th   e brains studied
Case Groups Age
(y) Sex Brain 
weight (g)
Braak stage 
(Aβ)
Braak 
stage 
(NFT)
1 Age-matched
 control
50 F 1,175 0 0
2 Age-matched
 control
50 M 1,278 0 0
3 Age-matched
 control
54 F 1,200 0 0
4 Age-matched
 control
56 M 1,275 0 0
5 Age-matched
 control
56 M 1,292 0 0
6 Age-matched
 control
56 M 1,405 0 0
7 Age-matched
 control
57 F 1,179 0 0
8 Age-matched
 control
59 M 1,415 0 0
9 Age-matched
 control
61 M 1,391 0 0
10 Age-matched
 control
61 F 1,212 0 0
11 Age-matched
 control
67 M 1,210 0 0
12 Age-matched
 control
71 M 1,300 0 0
13 Age-matched
 control
73 M 1,323 0 0
14 Age-matched
 control
79 F 1,280 0 0
15 AD 51 F 1,179 B 0
16 AD 55 M 1,380 B 0
17 AD 56 M 1,285 A 0
18 AD 60 F 1,200 B 0
19 AD 64 F 1,030 B 0
20 AD 67 M 1,148 A I
21 AD 68 M 1,280 B I
22 AD 69 M 1,440 B II
23 AD 72 M 1,390 B II
24 AD 76 M 1,350 A I
25 AD 76 M 1,340 B II
26 AD 79 F 1,200 B II
27 AD 79 F 1,220 B II
28 AD 83 F 1,264 B I
29 AD 87 F 1,220 A II
NFT, neurofi  brillary tangles; F, female; M, male; AD, Alzheimer’s disease.ErbB4 in the neurons of Alzheimer’s disease
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polyacrylamide gel electrophoresis and transferred to 
nitrocellulose membranes and subsequently blocked with 
TBS containing 5% nonfat powdered milk and 0.05% Tween 
20 for 1 hour. Following this, membranes were incubated 
overnight at 4°C with primary antibodies and developed using 
horseradish peroxidase-conjugated secondary antibodies 
and an enhanced chemiluminescence system (Amersham 
Pharmacia, Buckinghamshire, UK).
Statistical analysis
Within each region from three tissue sections, two images 
were captured at evenly spaced intervals to represent the 
entire anatomic area of interest. To determine the optical 
density of the immunoreactive cell, we used customized Image 
J software (NIH). Statistical analysis was conducted with 
Graph Pad Prism (GraphPad soft  ware, San Diego, CA, USA). 
Data were presented as means±standard error of the mean of 
were then incubated with Hoechst 33342 for 30 minutes and 
mounted. The images were visualized using the ErbB4 with 
FITC (green) fl  uorescence and Hoechst 33342 with UV (blue) 
fluorescence on the same sections, using a LSM 510 meta 
system (Zeiss LSM 510 laser scanning microscope, Carl Zeiss 
Inc.). To reduce auto fluorescence, the brain sections were 
incubated in 10% Sudan black B solution for 5 minutes, and 
then rinsed with disilled, deionized water (DW) and mounted 
with Vectashield [27].
       
Western blotting
Western blotting was carried out as previously described 
[17]. Briefly, cells were lysed in a modified RIPA buffer (50 
mM Tris-HCl [pH 7.4], 150 mM NaCl, 1% NP-40, 0.25% 
sodium-deoxycholate, 1 mM PMSF, 1 mM EDTA, 1 μg/
ml aprotinin, lepeptin, and pepstain protease inhibitors). 
Protein was then resolved using sodium dodecyl sulfate 
Fig. 1. Detailed analysis of pathological 
changes in Alzheimer’s disease (AD) 
brains. (A) Histological analysis of 
semi-serial paraffin sections from AD 
hippocamal formation. Hematoxylin   
and eosin staining (H&E), Luxol fast 
blue/cresyl violet (LFB-CV) staining, 
and modifi  ed Campbell’s silver staining 
is sequentially applied to the same 
sections, and the same fields at CA1. 
(B) Quantitative analysis of data in (A) 
that is neuronal loss of the hippocampal 
pyramidal neurons. Scale bars=100 μm. 
Shown are means±standard errors of the 
mean; n=14 for age-matched control 
and n=15 for AD. *P<0.05.Anat Cell Biol 2011;44:116-127 Ran-Sook Woo, et al 120
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Fig. 2. Expression of ErbB4 and p-ErbB4 in CA1-2 of hippocampus of Alzheimer’s disease (AD) brains. Paired low-power composites (A) and 
high-power (B) images of ErbB4 (left   column) and p-ErbB4 (right column) immunoreactivity in a single hippocampal tissue section. Inset, enlarged 
areas. (C) Quantitative analysis of data in (B) that is ErbB4 and p-ErbB4 expressing neurons. (D) ErbB4 confocal immunofl  orescence staining. 
Nuclei are stained with Hoechst 33342. (E) Quantitative analysis of data in (D) that are ErbB4 expressing neurons. Arrowheads, pyramidal 
neurons; IHC, immunohistochemistry. Scale bars=100 μm (A, B, D), 25 μm (inset [enlarged areas] of B). Shown are means±standard errors of the 
mean; n=14 for age-matched control and n=15 for AD. *P<0.05, **P<0.01.ErbB4 in the neurons of Alzheimer’s disease
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three or more independent experiments. For multiple group 
comparisons, statistical diff  erences were calculated using one-
way ANOVA followed by Bonferroni’s test. For comparison of 
means from the same group of cells, a Student’s paired t-test 
was used. Values of P<0.05 were considered signifi  cant.
Results
Immunohistochemical diagnosis in AD hippocampus
All brains (control and AD) were assigned Braak scores 
using neuropathological staging by Braak and Braak [28]. 
Th   e two braak groups are referred to as age-matched control 
(no pathologic sign) or AD (Braak stage I-II) referring to 
the extent of NFT and senile plaque in the hippocampus. 
Fig. 3. ErbB4 immunohistochemistry (IHC) in the corticomedial nucleus of amygdala, cholinergic neurons of the human basal forebrain (BFCN), 
and superior frontal gyrus of Alzheimer’s disease (AD) brains. (A, D) Hematoxylin and eosin (H&E), Luxol fast blue/cresyl violet (LFB-CV) and 
modifi  ed Campbell’s silver staining and ErbB4 immunoreactivity in the corticomedial nucleus of amygdala. (B, E) H&E, LFB-CV and modifi  ed 
Campbell’s silver staining and ErbB4 immunoreactivity in the BFCN. (C, F) H&E, LFB-CV and modifi  ed Campbell’s silver staining and ErbB4 
immunoreactivity in the superior frontal gyrus. (D-F) Quantitative analysis of data in (A-C) that are ErbB4 expressing neurons. Scale bars=100 
μm, 25 μm (inset [enlarged areas]). Shown are means± standard errors of the mean; n=14 for age-matched control and n=15 for AD. *P<0.05, 
**P<0.01.Anat Cell Biol 2011;44:116-127 Ran-Sook Woo, et al 122
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Postmortem examination confirmed the diagnosis of AD 
given the because the presence of abundant modified 
Campbell silver stained amyloid deposits and NFT; H&E and 
LFB-CV staining also demonstrated marked cell loss (Fig. 1A, 
B). 
        
Expression of ErbB4 in area CA1-2 transitional zone 
of hippocampus of AD brains
Previous biochemical studies have shown that NRG1 
exerts neuropreotective eff  ects in Alzheimer’s cell model via 
ErbB4 [29]. However, it is not clear ErbB4 immunoreactivity 
was changed in the neurons of AD brain. Since ErbB4 
immunoreactivity is associated with neuritic plaques [30], we 
hypothesized that ErbB4 immunoreactivity was changed in 
the neuron of hippocampal fi  elds of AD brains. As expected, 
ErbB4 immunoreactivity was significantly increased in the 
pyramidal neurons of the CA1-2 transitional field of AD 
brains as compared to age-matched controls (Fig. 2B, left 
column and 2C). As shown in Fig. 2B (right column) and 2C, 
phospho-ErbB4 immunoreactivity was also more increased 
in the same fields. At high magnification, the signal was 
revealed in pyramidal neurons. ErbB4 immunoreactivity 
was found primarily in pyramidal neurons; a subset of 
smaller, multipolar neurons was also observed. ErbB4 
immunoreactivity was further confirmed using confocal 
immunofluorescence on the same section. We found that 
the intensity of immunoreactivity of ErbB4 was higher in 
the neurons of the CA1-2 transitional field of AD brains as 
compared to age-matched controls (Fig. 2D, E). Th  ese  results 
are in agreement with observations above that detected with 
immunostaining method. Th   is suggests that ErbB4 mediated 
signaling is involved in AD processing.
Fig. 3. Continued.ErbB4 in the neurons of Alzheimer’s disease
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Expression of ErbB4 in the corticomedial nucleus of 
amygdala, BFCN, and superior frontal gyrus of AD 
brains
AD is strongly correlated with neuronal cell loss in the 
limbic structures, such as hippocampus and the amygdala, 
and the associated regions of cerebral cortex. To further 
determine whether ErbB4 immunoreactivity was changed in 
the corticomedial nucleus amygdala of AD brains. As shown 
in Fig. 3A and D, ErbB4 immunoreactivity was signifi  cantly 
increased in comparison to age-matched control. The 
cholinergic neurons of the human basal forebrain (BFCN) 
undergo selective loss in neurodegenerative disorders of 
the elderly, particularly AD [31]. Thus, we investigated the 
signals of ErbB4 in the neurons of BFCN. As shown in Fig. 3B 
and E, ErbB4 immunoreactivity was significantly increased 
in comparison to age-matched control. Unlike limbic 
stuructures, loss of pyramidal neurons in the laminae III and 
V of the superior fornatal gyrus was not severe in early AD. 
As AD progresses, the pyramidal neurons with apoptotic 
morphology (dark degeneration) appeared more in the layer 
V. As shown in Fig. 3C and F, ErbB4 immunoreactivity more 
intense in the pyramidal neuron of AD.
ErbB4 immunoreactivity was increased in the 
neurons of aging APPswe/PS1dE9 double transgenic 
mice
Double transgenic mice express a Swedish mutation (APP 
K595N/M596L) and a mutant human presenilin 1 (PSEN1dE9). 
Fig. 4. ErbB4 immunohistochemistry (IHC) in presenilin/amyloid precursor protein (PS/APP) mice. (A) Hematoxylin and eosin (H&E) and 
Aβ (6E10), ErbB4 immunoreactivity in the cortex and hippocampus. (B) Quantitative analysis of data in (A) that are ErbB4 expressing neurons. 
Scale bars=100 μm, 10 μm (inset [enlarged areas]). Shown are means±SEM; n=5 for age-matched control and n=5 for PS/APP mice. *P<0.01. 
(C) Immunoblot analysis of ErbB4 expression in cerebral cortex and hippocampus from PS/APP mice. AD, Alzheimer’s disease; Wt, wild type; Tg, 
transgenic.  Anat Cell Biol 2011;44:116-127 Ran-Sook Woo, et al 124
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APP/PS1 double transgenic mice develop numerous neuritic 
plaques throughout the hippocampus, entorhinal cortex (data 
not shown), and cerebral cortex (Fig. 4A). In cerebral cortex 
and hippocampus of APP/PS1 double transgenic mice, ErbB4 
immunoreactivity significantly increased in comparison to 
age-matched wild type control (Fig. 4A, B). Consistent with 
the ErbB4 expression observed in human AD, the intensity of 
immunoreactivity of ErbB4 was higher in the neuron of AD. 
To assess whether the level of expression of ErbB4 is altered 
in APP/PS1 double transgenic mice, lysates were prepared 
from the cerebral cortex and hippocampus. A protein of the 
expected 185 kD size was readily detected in immunoblots 
with the anti-ErbB4 antibody (Fig. 4C), but there were no 
differences in the level of ErbB4 expression in age-matched 
wild type control versus APP/PS1 double transgenic mice, in 
agreement with earlier studies [30].
Discussion
Several studies of the distribution of AD pathologic 
changes indicate that dementia affects predominantly the 
cerebral cortex; that subpopulation of neurons characterized 
by particular regional and laminar distributions, as well as 
distinct connectivity patterns, appears to be highly vulnerable 
[32, 33]. In addition, severe neuronal and synapse loss that 
mainly involves the hippocampal formation and association 
neocortical areas is also consistently observed in the brain 
of AD patients and has been shown to be a strong correlate 
of cognitive decline in demented people [34, 35]. Superior 
frontal gyrus is a part of motor association cortex which is 
related with judgment and planning in intellectual process. 
Basal forebrain cholinergic dysfunction is also a consistent 
feature of AD, which has been suggested to cause, at least 
partly, the cognitive deficits observed in patients with AD 
[31]. Th   e amygdala is a gray mass situated in the dorsomedial 
portion of the temporal lobe. It has been known that the 
amygdala is involved from the early AD. The cholinergic 
innervations of amygdala in human is severely aff  ected in case 
of AD [36]. 
Several previous studies have examined the localization 
of ErbB4. ErbB4 mRNA is enriched in regions where 
interneurons are clustered in rodent brains [37], and ErbB4 
protein was preferentially expressed at GABAergic terminals 
in the prefrontal cortex [16, 17]. We previously find highly 
increased ErbB4 protein in the apoptotic pyramidal neurons 
of hippocampus of the human brain relative to pathology 
staging [38]. Some recent reports have shown that ErbB4 
protein was expressed in the excitatory pyramidal neurons in 
the juvenile and adult monkeys [39]. Typically, layers III and 
V pyramidal neurons in cortical areas were marked by intense 
immunostaining in the adult human brain [40]. It appears 
that there are apparent species differences in the cerebral 
distribution of ErbB4. More work is needed to determine the 
neuronal subtypes that contain ErbB4. 
In this study, we examined the ErbB4 immunoreactivity in 
the predominantly vulnerable areas of AD. Th   e major fi  ndings 
of this study are as follows. First, ErbB4 and phospho-ErbB4 
immunoreactivities were signifi  cantly increased in the neurons 
of the CA1-2 transitional fi  eld of AD brains. Second, ErbB4 
expression was increased in the neurons of the corticomedial 
nucleus of the amygdala, BFCN, and the superior frontal 
gyrus of AD brains. 
As in the human brain, in the cerebral cortex and the 
hippocampus of APP/PS1 double transgenic mice, ErbB4 
immunoreactivity was signifi  cantly increased in comparison 
to age-matched wild type controls. In the brain, the pyramidal 
cell layer was strongly labeled in a dense plexus of GABAergic 
terminals and the boutons encircled the pyramidal cell bodies 
[41]. Interestingly, our study shows similar ErbB4 expression 
surrounding the soma of pyramidal-shaped neuron. This 
study provides evidence that ErbB4 may be present at 
GABAergic terminals. In this study, we found that increased 
ErbB4 immunoreactivity localized and surrounded the soma 
of pyramidal-shaped neurons. However, the identifi  cation of 
the neuronal subtype that expresses ErbB4 requires further 
investigation.
ErbB4 expression is widespread in various parts of the 
brain and nervous system [16, 17]. Recently, ErbB4 has been 
shown to play a key role in activity-dependent maturation 
and plasticity of excitatory synaptic function [12]. Further, 
NRG1 has been demonstrated to activate ErbB4 and regulate 
GABAergic transmission in adult brains [17]. Moreover, it 
was shown that NRG1 can be neuroprotective for cortical 
neurons [42], motor neurons [43], dopaminergic neurons 
[44], cochlear sensory neurons [45] and PC12 cells [29, 46]. 
It has also exhibited neuroprotection following ischemia 
[47-49]. These findings suggest that NRG1/ErbB4 signaling 
might be important in cognition, learning and memory 
formation through the modulation of synaptic plasticity and 
neuronal survival and is, therefore, a critical molecule in 
neurodegenerative disease. More work is needed to determine ErbB4 in the neurons of Alzheimer’s disease
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whether increased ErbB4 immunoreactivity is involved in 
neuroprotection or not.
Similar to APP, ErbB4 is a substrate for γ-secretase and as 
such, represents the first cleavage by TNF-alpha converting 
enzyme (TACE) to release a soluble extracellular peptide 
that contains the NRG1 binding site (ecto-ErbB4). The 
remaining membrane-anchored 80 kDa fragment (that is, 
ErbB4-CTF) is further cleaved in its transmembrane domain 
by presenilin-dependent γ-secretase to release the ErbB4 
intracellular domain (ErbB4-ICD), which has been shown 
to translocate to the nucleus and to regulate transcription 
[50, 51]. Recent studies have provided that β-site APP-
cleaving enzyme 1 (BACE1) participates in the proteolytic 
processing of NRG1 [52, 53] and involved in NRG1/ErbB4 
signaling [54]. Although, more studies is needed to determine 
whether BACE1-dependent NRG1 processing or γ-secretase-
dependent ErbB4 processing have a physiological function in 
central nervous system, it is possible that the balance between 
the generation of the APP intracellular domain and NRG1 or 
ErbB4-ICD are associated with brain disease including AD. 
The results of the current study suggest that NRG1/ErbB4 
signaling may be involved in AD neuropathology. However, 
a more detailed analysis is needed to determine whether 
alterations of ErbB4 expression are important event in AD 
pathology. Further investigation of ErbB4 signaling could be 
useful in understanding the pathogenesis of AD.
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